Missing Script

Get updates

MS-N131 · Supportive care · Human evidence · Appraised 25 October 2026

Can supervised sensorimotor or whole-body vibration training prevent CIPN during oxaliplatin or vinca-alkaloid chemotherapy?

Evidence at a glance

  • Evidence label: Promising preventive evidence from one multicenter randomized trial; replication is needed
  • Benefit: The STOP trial reported substantially less CIPN with both neuromuscular-training approaches than with usual care.
  • Certainty: Moderate for this specific trial population and protocol, but not yet high because one influential trial had substantial missing endpoint data and no participant blinding.
  • Risk: Sensorimotor work is generally low risk when supervised; whole-body vibration is unsuitable for some people with unstable bone metastases, acute thrombosis, recent cardiac disease or certain implants.

What was studied

Population and design: The STOP trial randomized 158 adults receiving first-line oxaliplatin or vinca alkaloids at four German centers: sensorimotor training (55), whole-body vibration (53) or usual care (50). Assessors were blinded; participants and therapists were not.

Studied regimen: Supervised sessions were given twice weekly for about 15–30 minutes during chemotherapy. The vibration protocol used four 30–60-second bouts at 18–35 Hz with 2–4 mm amplitude. This is a research regimen, not a personal exercise prescription.

What the evidence found

The primary endpoint was CIPN diagnosed with a structured neurologic assessment. Evaluable numbers were smaller than randomized numbers: CIPN occurred in 12 of 40 people assigned sensorimotor training (30.0%, 95% CI 17.9%–42.1%), 14 of 34 assigned vibration (41.2%, 27.9%–54.5%) and 24 of 34 receiving usual care (70.6%, 58.0%–83.2%; overall P=.002).

Results were similar in the per-protocol analysis, and the largest signal appeared among people receiving vinca alkaloids. Forty-three of 158 randomized participants dropped out, COVID-19 disrupted procedures and several secondary questionnaires were difficult to interpret.

How to interpret it

This is clinically meaningful initial evidence, not proof that every exercise program prevents CIPN. The endpoint used a trial-specific composite neurologic assessment, and missing data could affect estimates. The study cannot establish that the observed exploratory differences in chemotherapy dose reductions or mortality were caused by training.

Practical safety context

Exercise should be adapted for falls risk, thrombocytopenia, anemia, infection, cardiac limitations and bone disease. Whole-body vibration was specifically excluded for unstable bone metastases and acute leg thrombosis. New numbness or weakness should still be reported promptly because chemotherapy decisions may need review.

Questions for the care team

  • Which chemotherapy and baseline neuropathy risks apply here?
  • Can an oncology rehabilitation professional supervise the exact balance or vibration protocol?
  • What symptoms or falls-risk changes should trigger pausing training or reviewing chemotherapy?

Funding and conflicts

German Cancer Aid funded STOP and had no reported role in conduct or publication. Two authors reported outside speaker fees; no other disclosures were reported.

Sources

Last literature search: 25 October 2026. Record appraisal: 25 October 2026. This page is educational and does not replace individualized medical advice. Symptom or function improvement must not be interpreted as evidence of tumor response, delayed recurrence or longer survival.